This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.
Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility
by Zacks Equity Research
Mylan (MYL) recalls batches of blood pressure medicine in the United States. The company receives warning letter from the FDA for the manufacturing facility in Morgantown, WV.
Shire-Takeda Deal Gets Phase I Conditional European Approval
by Zacks Equity Research
Takeda's bid to acquire Shire (SHPG) receives conditional approval from the European Commission.
Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
by Zacks Equity Research
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $147.82 in the latest trading session, marking a +1.25% move from the prior day.
J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment
by Zacks Equity Research
Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
Stocks Stage a Late Rally to Take Some of the Sting Out of a Losing Week
by David Borun
With interest rates declining, investors turn their focus to Brexit and China trade negotiations
Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
by Zacks Equity Research
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $145.62 in the latest trading session, marking a +0.19% move from the prior day.
What's in the Cards for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.
Healthcare ETF (JHMH) Hits New 52-Week High
by Zacks Equity Research
This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?
Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.
AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.
Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down
by Zacks Equity Research
Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.
The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing
Democrats Hold Edge in House Battle: 5 Great Picks (Revised)
by Swarup Gupta
Drug and defense stocks would hugely benefit from a divided Congress.
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
by Zacks Equity Research
Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer
The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Facebook and Twitter
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Facebook and Twitter
5 Top Stocks to Make the Most of a Divided Congress
by Tirthankar Chakraborty
Gridlock in Washington bodes well for healthcare and defense stocks, which calls for investing in such a space for the time being.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $142.55 in the latest trading session, marking a +0.25% move from the prior day.
Beaten-Down Pharma ETFs to Buy Post Q3 Results
by Sweta Killa
Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices.
Election Day 2018: Here Are the Winners & Losers
by Tirthankar Chakraborty
One of the most awaited midterm elections in American history is upon us. Let's thus look at the sectors most likely to be impacted by the election results.
Democrats Hold Edge in House Battle: 5 Great Picks
by Swarup Gupta
Drug and defense stocks would hugely benefit from a divided Congress.
Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3